128 related articles for article (PubMed ID: 37353163)
1. Structural basis of CBP/p300 recruitment by the microphthalmia-associated transcription factor.
Brown AD; Vergunst KL; Branch M; Blair CM; Dupré DJ; Baillie GS; Langelaan DN
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119520. PubMed ID: 37353163
[TBL] [Abstract][Full Text] [Related]
2. The C-terminal transactivation domain of MITF interacts promiscuously with co-activator CBP/p300.
Brown AD; Lynch K; Langelaan DN
Sci Rep; 2023 Sep; 13(1):16094. PubMed ID: 37752231
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators.
Vachtenheim J; Sestáková B; Tuhácková Z
Pigment Cell Res; 2007 Feb; 20(1):41-51. PubMed ID: 17250547
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into TAZ2 domain-mediated CBP/p300 recruitment by transactivation domain 1 of the lymphopoietic transcription factor E2A.
Lochhead MR; Brown AD; Kirlin AC; Chitayat S; Munro K; Findlay JE; Baillie GS; LeBrun DP; Langelaan DN; Smith SP
J Biol Chem; 2020 Mar; 295(13):4303-4315. PubMed ID: 32098872
[TBL] [Abstract][Full Text] [Related]
5. β-Catenin interacts with the TAZ1 and TAZ2 domains of CBP/p300 to activate gene transcription.
Brown AD; Cranstone C; Dupré DJ; Langelaan DN
Int J Biol Macromol; 2023 May; 238():124155. PubMed ID: 36963539
[TBL] [Abstract][Full Text] [Related]
6. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
7. The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb.
Jansma AL; Martinez-Yamout MA; Liao R; Sun P; Dyson HJ; Wright PE
J Mol Biol; 2014 Dec; 426(24):4030-4048. PubMed ID: 25451029
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the transactivation domain of B-Myb with the TAZ2 domain of the coactivator p300: molecular features and properties of the complex.
Oka O; Waters LC; Strong SL; Dosanjh NS; Veverka V; Muskett FW; Renshaw PS; Klempnauer KH; Carr MD
PLoS One; 2012; 7(12):e52906. PubMed ID: 23300815
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein.
Ferreon JC; Martinez-Yamout MA; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2009 Aug; 106(32):13260-5. PubMed ID: 19651603
[TBL] [Abstract][Full Text] [Related]
10. CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding.
De Guzman RN; Wojciak JM; Martinez-Yamout MA; Dyson HJ; Wright PE
Biochemistry; 2005 Jan; 44(2):490-7. PubMed ID: 15641773
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains.
Wojciak JM; Martinez-Yamout MA; Dyson HJ; Wright PE
EMBO J; 2009 Apr; 28(7):948-58. PubMed ID: 19214187
[TBL] [Abstract][Full Text] [Related]
12. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
Jenkins LM; Yamaguchi H; Hayashi R; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Mazur SJ
Biochemistry; 2009 Feb; 48(6):1244-55. PubMed ID: 19166313
[TBL] [Abstract][Full Text] [Related]
13. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM
Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803
[TBL] [Abstract][Full Text] [Related]
14. Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein.
Krois AS; Ferreon JC; Martinez-Yamout MA; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1853-62. PubMed ID: 26976603
[TBL] [Abstract][Full Text] [Related]
15. Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.
Wang F; Marshall CB; Yamamoto K; Li GY; Gasmi-Seabrook GM; Okada H; Mak TW; Ikura M
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6078-83. PubMed ID: 22474372
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the RelA:CBP/p300 interaction reveals its involvement in NF-κB-driven transcription.
Mukherjee SP; Behar M; Birnbaum HA; Hoffmann A; Wright PE; Ghosh G
PLoS Biol; 2013 Sep; 11(9):e1001647. PubMed ID: 24019758
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into interactions of C/EBP transcriptional activators with the Taz2 domain of p300.
Bhaumik P; Davis J; Tropea JE; Cherry S; Johnson PF; Miller M
Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1914-21. PubMed ID: 25004968
[TBL] [Abstract][Full Text] [Related]
18. MITF: master regulator of melanocyte development and melanoma oncogene.
Levy C; Khaled M; Fisher DE
Trends Mol Med; 2006 Sep; 12(9):406-14. PubMed ID: 16899407
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.
Feng H; Jenkins LM; Durell SR; Hayashi R; Mazur SJ; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Bai Y
Structure; 2009 Feb; 17(2):202-10. PubMed ID: 19217391
[TBL] [Abstract][Full Text] [Related]
20. Expression of microphthalmia-associated transcription factor (MITF), which is critical for melanoma progression, is inhibited by both transcription factor GLI2 and transforming growth factor-β.
Pierrat MJ; Marsaud V; Mauviel A; Javelaud D
J Biol Chem; 2012 May; 287(22):17996-8004. PubMed ID: 22496449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
